Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Use of Brand Name for combination product
-
"Product A just received approval for new indication to be used in combination with Product B. The indication reads :
Product A (brand name) in combination with product B (generic name) is indicated for first-line treatment of....
When using Product A (brand name) in combination with product B (generic name), consult product monograph for Product B (Brand name) for further information on this drug.
Q: would we be able to use Product B's brand name and logo in the APS?"
-
If Product B is owned by the same sponsor as Product A, use of the brand name and logo is considered co-promotion. It may be used in the APS based on Product A’s indication but will require indication and fair balance for Product B at a minimum. Requirements will be determined by the content in the APS.
-
Thank you for your response. Would this still apply if Product B did not have the indication? or if the indication is expected soon?
-
Our previous response was provided with the understanding that Product B had a similar indication.
Where Product B does not have an indication at all, there can be issues with potential off-label promotion. It would be suggested to not use the Product B logo in Product A advertising in those cases. Use of Product B’s brand name could be considered when presented in the context of the PM for Product A, i.e. in a cautionary manner only. It should not be designed as co-promotion of Product B. As the respective indications and PM dictate how Product A and B can be presented, we suggest submitting for an opinion with the PMs as there may be nuances within that may not be addressed as a general question.
Eg. Product A is indicated for combination use with Product B for metastatic melanoma. Product B has no metastatic melanoma indication at all. If the APS is highlighting use in metastatic melanoma and includes Product B’s logo, this would be considered off-label promotion for metastatic melanoma as Product B has no such indication.
